

NCI Clinical Trials and Translational Research Advisory Committee
***Ad hoc* Strategic Planning Working Group**

Mission Statement

The National Cancer Institute (NCI) Clinical Trials and Translational Research Advisory Committee (CTAC) will convene an *ad hoc* Working Group to re-assess NCI's strategic vision for its clinical trials system for 2030 and beyond. The Working Group will review and address the capabilities of the clinical trials infrastructure necessary for achieving this vision as well as consider recommendations for relevant future CTAC activities.

Working Group membership will include CTAC members, as well as individuals from the scientific community with the appropriate expertise.

The Working Group will advise the Clinical Trials and Translational Research Advisory Committee and the NCI Director.